If you are building a long-term investment portfolio, focusing on high-quality ASX 200 shares with strong growth drivers can be a smart approach.
The best opportunities are often found in businesses with scale, strong management, and exposure to trends that can support earnings growth over many years.
Here are two ASX 200 shares that could be worth considering for the next five years.
ResMed Inc (ASX: RMD)
The first ASX 200 share that could be worth considering for the next five years is ResMed.
The sleep technology company is a global leader in devices and digital platforms used to treat sleep apnoea and other respiratory conditions. Its ecosystem combines medical devices, software, and cloud-connected data to help patients manage sleep-related health issues.
One of the most compelling aspects of the investment case is the size of the market opportunity. More than one billion people globally are estimated to suffer from sleep apnoea, yet a large portion of patients remain undiagnosed or untreated.
This underpenetrated market could provide a long runway for growth as awareness improves and diagnostic technology becomes more accessible. At the same time, wearable technology and digital health tools are helping identify more potential patients who may require treatment.
With strong global market leadership, a growing digital health ecosystem, and a massive addressable market, ResMed appears well positioned to continue expanding over the coming years.
Wesfarmers Ltd (ASX: WES)
Another ASX 200 share that could be worth considering by Aussie investors for the next five years is Wesfarmers.
The company is one of Australia’s leading conglomerates, with a portfolio of well-known businesses including Bunnings, Kmart, Priceline, Target, and Officeworks. These brands have strong market positions and generate consistent cash flow, providing a solid foundation for the group.
One of Wesfarmers’ key strengths is its disciplined capital allocation. Management has a track record of investing in growth opportunities while also returning capital to shareholders when appropriate.
In addition, the company has been investing in areas such as lithium and health, which could provide new avenues for growth beyond its core retail operations.
With a combination of defensive earnings from its retail businesses and optionality through new investments, Wesfarmers appears well placed to deliver steady returns over the next five years. This could make it worthy of a spot in a balanced investment portfolio.
The post 2 fantastic ASX 200 shares to buy and hold for the next five years appeared first on The Motley Fool Australia.
Should you invest $1,000 in ResMed Inc. right now?
Before you buy ResMed Inc. shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed Inc. wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why I’d buy these high-quality ASX 200 shares this week
- $20,000 of Wesfarmers shares can net me $820 in passive income!
- 3 dependable ASX shares to add to a superannuation fund in 2026
- How to build $100,000 a year in passive income from ASX shares
- Pulse check: How are the top 10 ASX 200 shares performing amid a new war?
Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed and Wesfarmers. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.